Applied BioCode (6598) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Applied BioCode (6598) has a cash flow conversion efficiency ratio of -0.029x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-19.88 Million ≈ $-626.20K USD) by net assets (NT$687.57 Million ≈ $21.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Applied BioCode - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Applied BioCode's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Applied BioCode (6598) financial obligations for a breakdown of total debt and financial obligations.
Applied BioCode Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Applied BioCode ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ferrum S.A.
BA:FERR
|
-0.007x |
|
MCT Bhd
KLSE:5182
|
0.003x |
|
Deniz Gayrimenkul Yatirim Ortakligi AS
IS:DZGYO
|
0.068x |
|
Estrella Immunopharma Inc.
NASDAQ:ESLA
|
0.017x |
|
Tai Roun Products Co Ltd
TW:1220
|
-0.040x |
|
Lee Feed Mill Public Company Limited
BK:LEE
|
0.019x |
|
DIGITAL CHOSUN Inc
KQ:033130
|
0.039x |
|
Exagen Inc
NASDAQ:XGN
|
0.162x |
Annual Cash Flow Conversion Efficiency for Applied BioCode (2013–2024)
The table below shows the annual cash flow conversion efficiency of Applied BioCode from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Applied BioCode (6598) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$878.83 Million ≈ $27.69 Million |
NT$-207.74 Million ≈ $-6.54 Million |
-0.236x | +23.82% |
| 2023-12-31 | NT$660.99 Million ≈ $20.82 Million |
NT$-205.09 Million ≈ $-6.46 Million |
-0.310x | -273.58% |
| 2022-12-31 | NT$816.07 Million ≈ $25.71 Million |
NT$145.87 Million ≈ $4.60 Million |
0.179x | +206.34% |
| 2021-12-31 | NT$902.96 Million ≈ $28.45 Million |
NT$-151.77 Million ≈ $-4.78 Million |
-0.168x | -24.51% |
| 2020-12-31 | NT$1.09 Billion ≈ $34.25 Million |
NT$-146.74 Million ≈ $-4.62 Million |
-0.135x | +77.17% |
| 2019-12-31 | NT$530.65 Million ≈ $16.72 Million |
NT$-313.84 Million ≈ $-9.89 Million |
-0.591x | +10.74% |
| 2018-12-31 | NT$432.73 Million ≈ $13.63 Million |
NT$-286.71 Million ≈ $-9.03 Million |
-0.663x | +26.82% |
| 2017-12-31 | NT$276.52 Million ≈ $8.71 Million |
NT$-250.36 Million ≈ $-7.89 Million |
-0.905x | +13.77% |
| 2016-12-31 | NT$427.60 Million ≈ $13.47 Million |
NT$-448.96 Million ≈ $-14.14 Million |
-1.050x | -35.65% |
| 2015-12-31 | NT$270.32 Million ≈ $8.52 Million |
NT$-209.24 Million ≈ $-6.59 Million |
-0.774x | -89.71% |
| 2014-12-31 | NT$315.69 Million ≈ $9.95 Million |
NT$-128.80 Million ≈ $-4.06 Million |
-0.408x | +24.14% |
| 2013-12-31 | NT$170.93 Million ≈ $5.39 Million |
NT$-91.93 Million ≈ $-2.90 Million |
-0.538x | -- |
About Applied BioCode
Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target us… Read more